| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2018 | TRIA BIOSCIENCE CORP. | 1616 Eastlake Ave E Ste 260 | Seattle | WA | 98102-3788 | KING | USA | R43IP001108 | Synthetic Universal Flu Vaccine | 04 | 1 | CDC | 10/2/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$70,143 ) |
| | 2023 | 2020 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 5 | NIH | 3/22/2023 | -$70,143 |
|
| Issue Date FY: 2021 ( Subtotal = -$522,382 ) |
| | 2021 | 2020 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 5 | NIH | 5/22/2021 | -$522,382 |
| | 2021 | 2018 | TRIA BIOSCIENCE CORP. | 1616 Eastlake Ave E Ste 260 | Seattle | WA | 98102-3788 | KING | USA | R43IP001108 | Synthetic Universal Flu Vaccine | 03 | 1 | CDC | 11/19/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,364,701 ) |
| | 2020 | 2020 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 001 | 5 | NIH | 2/11/2020 | $136,470 |
| | 2020 | 2020 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 5 | NIH | 12/5/2019 | $1,228,231 |
| | 2020 | 2018 | TRIA BIOSCIENCE CORP. | 1616 Eastlake Ave E Ste 260 | Seattle | WA | 98102-3788 | KING | USA | R43IP001108 | Synthetic Universal Flu Vaccine | 02 | 1 | CDC | 3/24/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,365,834 ) |
| | 2019 | 2019 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 001 | 4 | NIH | 12/3/2018 | $1,365,834 |
| | 2019 | 2018 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 3 | NIH | 10/20/2018 | -$51,512 |
| | 2019 | 2018 | TRIA BIOSCIENCE CORP. | 1616 Eastlake Ave E Ste 260 | Seattle | WA | 98102-3788 | KING | USA | R43IP001108 | Synthetic Universal Flu Vaccine | 01 | 1 | CDC | 11/19/2018 | $0 |
| | 2019 | 2016 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH2DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 2 | NIH | 10/20/2018 | $51,512 |
|
| Issue Date FY: 2018 ( Subtotal = $1,604,887 ) |
| | 2018 | 2018 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 001 | 3 | NIH | 5/24/2018 | $121,655 |
| | 2018 | 2018 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 3 | NIH | 11/6/2017 | $1,379,921 |
| | 2018 | 2018 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH3DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 002 | 3 | NIH | 8/29/2018 | $0 |
| | 2018 | 2018 | Tria Bioscience Corp. | 1616 Eastlake Ave E Ste 260 | Seattle | WA | 98102-3788 | KING | USA | R43IP001108 | Synthetic Universal Flu Vaccine | 00 | 1 | CDC | 9/7/2018 | $224,966 |
| | 2018 | 2016 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH2DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 2 | NIH | 11/6/2017 | $0 |
| | 2018 | 2016 | TRIA BIOSCIENCE CORP. | 1616 EASTLAKE AVE E STE 260 | SEATTLE | WA | 98102-3788 | KING | USA | UH2DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 001 | 2 | NIH | 5/24/2018 | -$121,655 |
|
| Issue Date FY: 2016 ( Subtotal = $1,175,877 ) |
| | 2016 | 2016 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | UH2DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 001 | 2 | NIH | 7/19/2016 | $1,024,634 |
| | 2016 | 2015 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | UH2DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 1 | NIH | 6/24/2016 | $151,243 |
|
| Issue Date FY: 2015 ( Subtotal = $1,022,939 ) |
| | 2015 | 2015 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | UH2DA041162 | Preclinical development of a TriCoil-based nicotine vaccine | 000 | 1 | NIH | 9/8/2015 | $1,022,939 |
|
| Issue Date FY: 2014 ( Subtotal = $280,636 ) |
| | 2014 | 2014 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI104178 | Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients | 000 | 2 | NIH | 7/11/2014 | $280,636 |
|
| Issue Date FY: 2013 ( Subtotal = $1,800,137 ) |
| | 2013 | 2013 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI098290 | CROSS-PROTECTIVE MONOCLONAL ANTIBODIES FOR TREATMENT OF PANDEMIC FLU | 000 | 2 | NIH | 7/19/2013 | $300,000 |
| | 2013 | 2013 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R44AI081383 | PROTECTIVE VACCINE FOR H5N1 FLU USING H5 PROTEIN AND A NOVEL TLR4 AGONIST. | 000 | 5 | NIH | 2/25/2013 | $1,000,000 |
| | 2013 | 2013 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI104178 | Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients | 000 | 1 | NIH | 8/6/2013 | $298,747 |
| | 2013 | 2013 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43DA033845 | ADVANCED DESIGN OF A NICOTINE VACCINE FOR SMOKING CESSATION | 000 | 2 | NIH | 7/16/2013 | $201,390 |
|
| Issue Date FY: 2012 ( Subtotal = $1,451,451 ) |
| | 2012 | 2012 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI098290 | CROSS-PROTECTIVE MONOCLONAL ANTIBODIES FOR TREATMENT OF PANDEMIC FLU | 000 | 1 | NIH | 7/31/2012 | $300,000 |
| | 2012 | 2012 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI098290 | CROSS-PROTECTIVE MONOCLONAL ANTIBODIES FOR TREATMENT OF PANDEMIC FLU | 001 | 1 | NIH | 8/15/2012 | $300,000 |
| | 2012 | 2012 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI098290 | CROSS-PROTECTIVE MONOCLONAL ANTIBODIES FOR TREATMENT OF PANDEMIC FLU | 001 | 1 | NIH | 8/15/2012 | -$300,000 |
| | 2012 | 2012 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43DA033845 | ADVANCED DESIGN OF A NICOTINE VACCINE FOR SMOKING CESSATION | 000 | 1 | NIH | 7/26/2012 | $151,451 |
| | 2012 | 2012 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R44AI081383 | PROTECTIVE VACCINE FOR H5N1 FLU USING H5 PROTEIN AND A NOVEL TLR4 AGONIST. | 000 | 4 | NIH | 3/2/2012 | $1,000,000 |
| | 2012 | 2012 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R44AI081383 | PROTECTIVE VACCINE FOR H5N1 FLU USING H5 PROTEIN AND A NOVEL TLR4 AGONIST. | 001 | 4 | NIH | 8/15/2012 | $1,000,000 |
| | 2012 | 2012 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R44AI081383 | PROTECTIVE VACCINE FOR H5N1 FLU USING H5 PROTEIN AND A NOVEL TLR4 AGONIST. | 001 | 4 | NIH | 8/15/2012 | -$1,000,000 |
|
| Issue Date FY: 2011 ( Subtotal = $1,300,000 ) |
| | 2011 | 2011 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI087444 | A NOVEL DC-TARGETING NON-INTEGRATING LENTIVECTOR VACCINE FOR HIV INFECTION | 000 | 2 | NIH | 5/3/2011 | $300,000 |
| | 2011 | 2011 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R44AI081383 | PROTECTIVE VACCINE FOR H5N1 FLU USING H5 PROTEIN AND A NOVEL TLR4 AGONIST. | 000 | 3 | NIH | 2/25/2011 | $1,000,000 |
| | 2011 | 2010 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI081383 | PANDEMIC H5N1 VACCINE CONTAINING RECOMBINANT H5 AND A SYNTHETIC TLR4 AGONIST, GLA | 000 | 2 | NIH | 2/24/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $616,224 ) (Continued on the next page) |
| | 2010 | 2010 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI081383 | PANDEMIC H5N1 VACCINE CONTAINING RECOMBINANT H5 AND A SYNTHETIC TLR4 AGONIST, GLA | 001 | 2 | NIH | 9/2/2010 | $316,224 |
| | 2010 | 2010 | TRIA BIOSCIENCE CORPORATION | 1124 COLUMBIA STREET | SEATTLE | WA | 98104 | KING | USA | R43AI087444 | A NOVEL DC-TARGETING NON-INTEGRATING LENTIVECTOR VACCINE FOR HIV INFECTION | 000 | 1 | NIH | 4/28/2010 | $300,000 |
|
